Education
About Us
Working with TipRanks
Follow Us
Kuros Biosciences Ltd. (CH:KURN)
:KURN
Total Valuation
Kuros Biosciences has a market cap or net worth of CHF943.44M. The enterprise value is CHF931.62M.
Market CapCHF943.44M
Enterprise ValueCHF931.62M
Share Statistics
Kuros Biosciences has 39,179,276 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding39,179,276
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Kuros Biosciences’s return on equity (ROE) is 0.03 and return on invested capital (ROIC) is 4.84%.
Return on Equity (ROE)0.03
Return on Assets (ROA)0.02
Return on Invested Capital (ROIC)4.84%
Return on Capital Employed (ROCE)0.10
Revenue Per Employee994.26K
Profits Per Employee16.76K
Employee Count122
Asset Turnover1.13
Inventory Turnover0.98
Valuation Ratios
The current PE Ratio of Kuros Biosciences is 498.6. Kuros Biosciences’s PEG ratio is -3.21.
PE Ratio498.6
PS Ratio8.71
PB Ratio15.78
Price to Fair Value15.78
Price to FCF-439.50
Price to Operating Cash Flow-1.29K
PEG Ratio-3.21
Income Statement
In the last 12 months, Kuros Biosciences had revenue of 121.30M and earned 2.12M in profits. Earnings per share was 0.06.
Revenue121.30M
Gross Profit104.79M
Operating Income7.33M
Pretax Income4.16M
Net Income2.12M
EBITDA10.13M
Earnings Per Share (EPS)0.06
Cash Flow
In the last 12 months, operating cash flow was -732.83K and capital expenditures -2.10M, giving a free cash flow of -2.83M billion.
Operating Cash Flow-732.83K
Free Cash Flow-2.83M
Free Cash Flow per Share-0.07
Dividends & Yields
Kuros Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.40
52-Week Price Change21.01%
50-Day Moving Average26.46
200-Day Moving Average27.25
Relative Strength Index (RSI)38.98
Average Volume (3m)128.87K
Important Dates
Kuros Biosciences upcoming earnings date is Aug 12, 2026, TBA (Confirmed).
Last Earnings DateMar 10, 2026
Next Earnings DateAug 12, 2026
Ex-Dividend Date―
Financial Position
Kuros Biosciences as a current ratio of 1.96, with Debt / Equity ratio of 5.88%
Current Ratio1.96
Quick Ratio1.45
Debt to Market Cap<0.01
Net Debt to EBITDA-1.16
Interest Coverage Ratio24.04
Taxes
In the past 12 months, Kuros Biosciences has paid 2.12M in taxes.
Income Tax2.12M
Effective Tax Rate0.51
Enterprise Valuation
Kuros Biosciences EV to EBITDA ratio is 103.14, with an EV/FCF ratio of -434.62.
EV to Sales8.61
EV to EBITDA103.14
EV to Free Cash Flow-434.62
EV to Operating Cash Flow-2.76K
Balance Sheet
Kuros Biosciences has CHF15.66M in cash and marketable securities with CHF3.94M in debt, giving a net cash position of CHF11.72M billion.
Cash & Marketable SecuritiesCHF15.66M
Total DebtCHF3.94M
Net CashCHF11.72M
Net Cash Per ShareCHF0.30
Tangible Book Value Per ShareCHF0.90
Margins
Gross margin is 87.02%, with operating margin of 6.04%, and net profit margin of 1.75%.
Gross Margin87.02%
Operating Margin6.04%
Pretax Margin3.43%
Net Profit Margin1.75%
EBITDA Margin8.35%
EBIT Margin6.04%
Analyst Forecast
The average price target for Kuros Biosciences is CHF36.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetCHF36.50
Price Target Upside29.62% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast104.01%
EPS Growth Forecast33.25%